Serum Cell Death Biomarkers for Prediction of Liver Fibrosis and Poor Prognosis in Primary Biliary Cirrhosis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The development of simple, noninvasive markers of liver fibrosis is urgently needed for primary biliary cirrhosis (PBC). This study examined the ability of several serum biomarkers of cell death to estimate fibrosis and prognosis in PBC. A cohort of 130 patients with biopsy-proven PBC and 90 healthy subjects were enrolled. We assessed the utility of the M30 ELISA, which detects caspase-cleaved cytokeratin-18 (CK-18) fragments and is representative of apoptotic cell death, as well as the M65 and newly developed M65 Epideath (M65ED) ELISAs, which detect total CK-18 as indicators of overall cell death, in predicting clinically relevant fibrosis stage. All 3 cell death biomarkers were significantly higher in patients with PBC than in healthy controls and were significantly correlated with fibrosis stage. The areas under the receiver operating characteristic curve for the M65 and M65ED assays for differentiation among significant fibrosis, severe fibrosis, and cirrhosis were 0.66 and 0.76, 0.66 and 0.73, and 0.74 and 0.82, respectively. In multivariate analysis, high M65ED (hazard ratio 6.13; 95% confidence interval 1.18-31.69; P = 0.031) and severe fibrosis (hazard ratio 7.45; 95% confidence interval 1.82-30.51; P = 0.005) were independently associated with liver-related death, transplantation, or decompensation. High serum M65ED was also significantly associated with poor outcome in PBC (log-rank test; P = 0.001). Noninvasive cell death biomarkers appear to be clinically useful in predicting fibrosis in PBC. Moreover, the M65ED assay may represent a new surrogate marker of adverse disease outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Serum levels of wisteria floribunda agglutinin-positive mac-2 binding protein (WFA + -M2BP) and cytokeratin 18 have also shown prognostic ability in PBC, but validation is required [84,85].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Molecular mechanisms of necroptosis: an ordered cellular explosion
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., & Kroemer, G. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2970 · Cited by 2,382
Bravo, A. A., Sheth, S. G., & Chopra, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440706 · Cited by 2,041
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey
Cadranel, J.-F., Rufat, P., & Degos, F. (2000) · Hepatology · doi:10.1053/jhep.2000.16602 · Cited by 993
(2015) · Diagnostic Imaging: Gastrointestinal · doi:10.1016/b978-0-323-37755-3.50202-6 · Cited by 811
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Cited by
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
“Serum levels of wisteria floribunda agglutinin-positive mac-2 binding protein (WFA-M2BP) and cytokeratin 18 have also shown prognostic ability in PBC, but validation is required [84,85].”
Cell death markers in patients with cirrhosis and acute decompensation
Macdonald, S., Andreola, F., Bachtiger, P., Amoros, A., Pavesi, M., Mookerjee, R., Zheng, Y. B., Gronbaek, H., Gerbes, A. L., Sola, E., et al. (2018) · Hepatology · doi:10.1002/hep.29581 · Cited by 99
“Markers of cell death, in particular, caspase-cleaved keratin 18 (cK18) and keratin 18 (K18), have been previously demonstrated to be clinically relevant in the diagnosis, assessment of disease severity, and prognosis of a wide range of acute and chronic liver diseases, including chronic and acute on chronic hepatitis…”
BackgroundHöfer, A., Jonigk, D. D., Hartleben, B., Verboom, M., Hallensleben, M., Manns, M. P., Jaeckel, E., & Taubert, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-70938-7 · Cited by 37
Alt, Y., Grimm, A., Schlegel, L., Grambihler, A., Kittner, J. M., Wiltink, J., Galle, P. R., Wörns, M., & Schattenberg, J. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151200 · Cited by 32
Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis
Chen, S., Wan, Q.-S., Wang, T., & Zhang, K.-H. (2020) · BioMed Research International · doi:10.1155/2020/7170457 · Cited by 30
“[44] detected M30, M65, and M65EpiDeath in 130 PBC patients and found that they were all significantly higher in PBC than in healthy controls and were significantly correlated with fibrosis stage; the mortality was significantly higher in patients with high M65EpiDeath levels (HR: 6.”
BackgroundWaidmann, O., Brunner, F., Herrmann, E. M., Zeuzem, S., Piiper, A., & Kronenberger, B. (2016) · Liver International · doi:10.1111/liv.13117 · Cited by 24
“A similar prognostic role of M65EpiDeath has been recently reported by a study performed in patients with primary biliary cirrhosis (16).”
BackgroundXiang, D., Liu, Y., Zu, Y. X., Yang, J., He, W., Zhang, C., & Liu, D. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115854 · Cited by 26
Fujinaga, Y., Namisaki, T., Takaya, H., Tsuji, Y., Suzuki, J., Shibamoto, A., Kubo, T., Iwai, S., Tomooka, F., Takeda, S., et al. (2021) · Medicine · doi:10.1097/md.0000000000027403 · Cited by 23
“on the principle, sampling error, and cost.([32,33]) Therefore, noninvasive methods of assessing liver fibrosis are required to overcome these limitations.”
BackgroundLiver fibrosis progression predicts survival in patients with primary biliary cirrhosis
Namisaki, T., Moriya, K., Noguchi, R., Kitade, M., Kawaratani, H., Yamao, J., Mitoro, A., Yoshida, M., Sawai, M., Uejima, M., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12746 · Cited by 23
Biomarkers for primary biliary cholangitis: current perspectives
Kouroumalis, E., Samonakis, D., & Voumvouraki, A. (2018) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s135337 · Cited by 26
“a newly developed M65ED ELISA were associated with poor clinical outcome at a cutoff value of 672 UI/L.(69)”
Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases
Corpechot, C. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.08.013 · Cited by 19
Emerging drugs for the treatment of Primary Biliary Cholangitis
Ali, A. H., Tabibian, J. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1150999 · Cited by 19
“Serum fibrosis parameters have been proposed as biomarkers of treatment response and disease progression, but are yet to be validated.[53,54] The enhanced liver fibrosis assay (ELF assay) has been shown to be superior to the Mayo risk score and the Model for End-Stage Liver Disease (MELD) in predicting clinical progre…”
MethodCao, Z., Li, J., Wang, Y., Bao, R., Liu, Y.-H., Xiang, X., Lin, L., Ye, F., Lu, J. L., Xie, Q., et al. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.07.037 · Cited by 13
Wei, X., Wei, H., Lin, W., Hu, Z., & Zhang, J. (2017) · Medicine · doi:10.1097/md.0000000000006807 · Cited by 10
Measuring Apoptosis and Necrosis in Cholestatic Liver Injury
Woolbright, B. L., & Jaeschke, H. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9420-5_9 · Cited by 10
Risk Stratification in Primary Biliary Cholangitis
Martini, F., Balducci, D., Mancinelli, M., Buzzanca, V., Fracchia, E., Tarantino, G., Benedetti, A., Marzioni, M., & Maroni, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175713 · Cited by 14
Huang, L.-X., Wang, Z., Jin, R., Chen, H., & Feng, B. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2153672 · Cited by 14
“Studies also illustrate that baseline cirrhosis [112], significant duct loss [58], and advanced histological stage [57,76] are associated with poor UDCA response, which suggest that disease severity and progression should be a privilege consideration in the LAMP-2, lysosome-associated membrane protein 2; M65, cytokera…”
BackgroundHayashi, M., Abe, K., Fujita, M., Okai, K., Takahashi, A., Nozawa, Y., & Ohira, H. (2018) · Medical Molecular Morphology · doi:10.1007/s00795-018-0184-0 · Cited by 9
Piecha, F., Jahn, B.-V., Köntopf, J., Koop, A. C., Ozga, A., Jawazneh, A. A., Harberts, A., Riedel, C., Buggisch, P., Benten, D., et al. (2024) · Liver International · doi:10.1111/liv.16156 · Cited by 8
“Specifically, m30 and m65 have been established as a diagnostic tool for the severity of steatotic liver disease [11, 17, 29, 30] and primary biliary cholangitis [14].”
Chen, J., Hu, J., Zhuang, J., Li, Z., Peng, S., Huang, X., & Zhuang, J. (2025) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70034 · Cited by 6
Jiang, M., Yan, X., Song, X., Yan, Q., Zhao, Y., Wang, L., & Gao, P. (2020) · Medicine · doi:10.1097/md.0000000000020502 · Cited by 7
Derben, F. C., Engel, B., Zachou, K., Hartl, J., Hartleben, B., Bantel, H., Schramm, C., Dalekos, G. Ν., Manns, M. P., Jaeckel, E., et al. (2020) · Liver International · doi:10.1111/liv.14699 · Cited by 6
“Time in remission, months; median (range) 46 (1-161) (n = 57) 47 (10-161) (n = 30) 46 (1-123) (n = 27)”
BackgroundInfluentialCytokeratin 18 fragment in liver inflammation and fibrosis: Systematic review and meta-analysis
Ye, J., Lai, J., Luo, L., Zhou, T., Sun, Y., & Zhong, B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120147 · Cited by 7
The changing faces of cholangitis
Lee, S. P., Roberts, J. R., & Kuver, R. (2016) · F1000Research · doi:10.12688/f1000research.8745.1 · Cited by 4
Suzuki, H., Joshita, S., Hirayama, A., Shinji, A., Mukawa, K., Sako, M., Yoshimura, N., Suga, T., Umemura, T., Ashihara, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69370-8 · Cited by 3
Self-citationThe efficacy of serum cell death biomarkers for diagnosing biliary tract cancer
Sugimoto, M., Abe, K., Hayashi, M., Takagi, T. J., Suzuki, R., Konno, N., Asama, H., Sato, Y., Irie, H., Watanabe, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35278-7 · Cited by 2
Xiang, D., Liu, Y., Zu, Y. X., Yang, J., He, W., Zhang, C., & Liu, D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4165305
Metadata
- Authors
- Sekiguchi, T., Umemura, T., Fujimori, N., Shibata, S., Ichikawa, Y., Kimura, T., Joshita, S., Komatsu, M., Matsumoto, A., Tanaka, E., & Ota, M.
- Affiliations
- Shinshu University (JP)
- Corresponding author
- Umemura, Takeji
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-25
- Volume
- 10
- Issue
- 6
- Pages
- e0131658
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4482393
- OpenAlex
- W828765355
- Cited by
- 27
- References
- 39
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 5 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 6 · 2015: 1
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (15H01803, 26460996)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- primary biliary cirrhosis, liver fibrosis, cell death biomarkers, cytokeratin 18, apoptosis, noninvasive fibrosis staging, prognosis, liver-related mortality, liver transplantation, hepatic decompensation
- MeSH terms
- Aged, Biopsy, Enzyme-Linked Immunosorbent Assay, Female, Humans, Japan, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Prognosis, ROC Curve, Biomarkers, Case-Control Studies, Treatment Outcome, Cell Death, Apoptosis, Kaplan-Meier Estimate, Keratin-18
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.